Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENLV |
---|---|---|
09:32 ET | 2718 | 1.3799 |
09:34 ET | 1988 | 1.3887 |
09:36 ET | 1100 | 1.37 |
09:59 ET | 100 | 1.375 |
10:01 ET | 1300 | 1.37 |
10:03 ET | 656 | 1.36 |
10:06 ET | 100 | 1.36 |
10:14 ET | 100 | 1.36 |
10:39 ET | 2900 | 1.3599 |
11:09 ET | 478 | 1.3593 |
11:15 ET | 778 | 1.3401 |
11:20 ET | 900 | 1.3597 |
11:27 ET | 600 | 1.35 |
11:38 ET | 500 | 1.3598 |
11:49 ET | 1070 | 1.36 |
11:58 ET | 100 | 1.37 |
12:12 ET | 3062 | 1.4 |
12:16 ET | 1091 | 1.39 |
12:25 ET | 100 | 1.39 |
12:34 ET | 4475 | 1.39 |
12:36 ET | 3100 | 1.39 |
12:45 ET | 200 | 1.39 |
12:52 ET | 3454 | 1.4 |
12:57 ET | 3234 | 1.3901 |
01:12 ET | 300 | 1.3908 |
01:21 ET | 1143 | 1.41 |
01:24 ET | 1957 | 1.42 |
01:30 ET | 1101 | 1.43 |
01:32 ET | 3342 | 1.4467 |
01:33 ET | 250 | 1.425 |
02:02 ET | 1979 | 1.45 |
02:04 ET | 2437 | 1.45 |
02:06 ET | 1907 | 1.46 |
02:09 ET | 200 | 1.44 |
02:18 ET | 100 | 1.45 |
03:09 ET | 4139 | 1.48 |
03:14 ET | 200 | 1.46 |
03:16 ET | 103 | 1.47 |
03:23 ET | 392 | 1.47 |
03:25 ET | 8968 | 1.49 |
03:27 ET | 300 | 1.49 |
03:32 ET | 557 | 1.4846 |
03:36 ET | 8700 | 1.44 |
03:45 ET | 1211 | 1.4601 |
03:52 ET | 1000 | 1.4799 |
03:56 ET | 800 | 1.4622 |
03:59 ET | 663 | 1.479 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enlivex Therapeutics Ltd | 29.3M | -0.9x | --- |
BioVie Inc | 30.2M | -0.5x | --- |
Lisata Therapeutics Inc | 30.5M | -1.4x | --- |
Raphael Pharmaceutical Inc | 30.6M | -17.7x | --- |
Brainstorm Cell Therapeutics Inc | 30.7M | -1.4x | --- |
Cocrystal Pharma Inc | 27.7M | -1.6x | --- |
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $27.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.